Use of corticosteroids in pulmonary leptospirosis: a randomised double-blind clinical trial

Submission date	Recruitment status	Prospectively registered		
25/03/2008	No longer recruiting	[X] Protocol		
Registration date	Overall study status	Statistical analysis plan		
16/05/2008	Completed	Results		
Last Edited	Condition category	Individual participant data		
23/10/2020	Infections and Infestations	Record updated in last year		

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Ana Flávia Azevedo

Contact details

Rua Professor Augusto Lins e Silva 228/901 Boa Viagem Recife Brazil 81030-030

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

FR-167386

Study information

Scientific Title

Use of corticosteroids in pulmonary leptospirosis: a randomised double-blind clinical trial

Acronym

ARDS

Study objectives

Pulse therapy with corticosteroids leads to better results in pulmonary leptospirosis, reducing pulmonary infiltrate, occurrence of pulmonary haemorrhage, number of days in mechanical ventilation, incidence of acute respiratory failure, occurrence of secondary respiratory infection and mortality.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethical Committee of Research, Health Science Department, Federal University of Pernambuco (Comitê de Ética em Pesquisa, Centro de Ciências da Saúde, Universidade Federal de Pernambuco) Date of approval: 22/02/2008 (ref: CEP/CCS/UFPE N° 416/07)

Study design

Randomised, double-blind, controlled trial.

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Leptospirosis

Interventions

Patients will be randomised to either methylprednisolone or placebo in blocks of four according to a random number generator. The randomisation ratio was 2 (methylprednisolone) to 1 (placebo). The participants and the medical staff were blinded throughout the study.

Intervention group: 1 g methylprednisolone per day intravenously for three consecutive days Control group: Placebo intravenously for three consecutive days

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Methylprednisolone

Primary outcome measure

Mortality, recorded during the whole hospitalisation period.

Secondary outcome measures

- 1. Outcome of pulmonary leptospirosis after corticosteroids administration, assessed during the first seven days and then on the 14th and 28th day, by clinical and radiological assessment, and PaO2/FiO2 and haemoglobin/haematocrit evaluation.
- 2. Number of days in mechanical ventilation
- 3. Number of days in hospital
- 4. Number of days in UCI
- 5. Respiratory infection, monitored during the first seven days and then on the 14th and 28th day, by clinical and radiological assessment, and PaO2/FiO2 and leukocyte evaluation.
- 6. Other respiratory complications, monitored during the first seven days and then on the 14th and 28th day, by clinical and radiological assessment, and the PaO2/FiO2 evaluation.
- 7. Other infectious complications, monitored during the first seven days and then on the 14th and 28th day
- 8. Adverse events associated with corticosteroid administration, monitored during the first seven days and then on the 14th and 28th day

Overall study start date

01/04/2008

Completion date

31/12/2009

Eligibility

Key inclusion criteria

- 1. Both males and females
- 2. Diagnosis of leptospirosis: Abrupt fever and myalgia, jaundice, normal number of leucocytes or increased number of leucocytes, thrombocytopenia, high levels of muscle enzymes and lack of hyperkalemia
- 3. Diagnosis of pulmonary leptospirosis: Interstitial pulmonary infiltrate or alveolo interstitial bilateral, associated with at least one of the following:
- 1. Changes in respiratory
- 2. Cough
- 3. Dyspnea

- 4. Decrease of haemoglobin
- 5. Haemoptysis
- 6. Hypoxemia (PO2/FiO2 <300)

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

266 patients

Key exclusion criteria

- 1. Age under 15 years old
- 2. History of hypersensitivity to corticosteroids
- 3. Pregnancy
- 4. History of active tuberculosis or fungal infection
- 5. Recent history of head trauma
- 6. Neurosurgery
- 7. Peptic ulcer disorder
- 8. Enrolled in another trial

Date of first enrolment

01/04/2008

Date of final enrolment

31/12/2009

Locations

Countries of recruitment

Brazil

Study participating centre Rua Professor Augusto Lins e Silva

Recife Brazil 81030-030

Sponsor information

Organisation

Federal University of Pernambuco (Universidade Federal de Pernambuco [UFPE]) (Brazil)

Sponsor details

Av. Prof. Moraes Rego 1235 Cidade Universitária Recife Brazil 50670-901

Sponsor type

University/education

Website

http://www.ufpe.br

ROR

https://ror.org/047908t24

Funder(s)

Funder type

University/education

Funder Name

Federal University of Pernambuco (Universidade Federal de Pernambuco [UFPE]), Clinical Hospital (Brazil)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<u>Protocol article</u>	protocol	30/06/2011	23/10/2020	Yes	No